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Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Cardiff, UK
Abstract
Bone morphogenetic proteins (BMPs) belong to the TGF-β super family, and are essential 
for the regulation of foetal development, tissue differentiation and homeostasis and a 
multitude of cellular functions. Naturally, this has led to the exploration of aberrance 
in this highly regulated system as a key factor in tumourigenesis. Originally identiied 
for their role in osteogenesis and bone turnover, attention has been turned to the 
potential role of BMPs in tumour metastases to, and progression within, the bone niche. 
This is particularly pertinent to breast cancer, which commonly metastasises to bone, 
and in which studies have revealed aberrations of both BMP expression and signalling, 
which correlate clinically with breast cancer progression. Ultimately a BMP proile could 
provide new prognostic disease markers. As the evidence suggests a role for BMPs in 
regulating breast tumour cellular function, in particular interactions with tumour stroma 
and the bone metastatic microenvironment, there may be novel therapeutic potential 
in targeting BMP signalling in breast cancer. This review provides an update on the 
current knowledge of BMP abnormalities and their implication in the development and 
progression of breast cancer, particularly in the disease-speciic bone metastasis.
Introduction
Breast cancer is the most common cancer in women 
worldwide (Ferlay et al. 2015). In developed countries, it 
receives media coverage and research funding above all 
other cancers (Konfortion et  al. 2014, American Cancer 
Society 2016) and thus continual progress is made in 
understanding tumour biology, developing diagnostics 
and improved therapeutics. Despite progress, 15% of 
patients diagnosed with metastatic breast cancer survive 
5 years, compared to 99% of stage I breast cancers (Cancer 
Research UK 2017). Even for those treated at an early 
stage, there is still a signiicant risk of relapse, often several 
years later. This is particularly true of oestrogen receptor-
positive breast cancers, which are at a particular risk of 
late relapse (Yamashita et al. 2016). The leading metastatic 
site is bone, which holds the majority of tumour burden 
at death (Awolaran et  al. 2016). Osteolytic lesions lead 
to bone pain, fractures, spinal cord compression and 
hypercalcaemia, reducing quality and length of life for the 
patient. Symptomatic management includes inhibition of 
osteoclast activity, swinging the balance of bone turnover 
away from osteolysis.
Known since 1965 as a key regulator of bone 
development and turnover, bone morphogenetic proteins 
(BMPs) have more recently been implicated in bone 
metastasis of many solid tumours (Ye et al. 2007b, Davis 
et  al. 2016). Given the propensity for breast cancer to 
metastasise to bone makes BMPs of particular interest in 
this area. Their inluence on breast tumour biology may 
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also extend well beyond the bone microenvironment, 
opening avenues for targeted therapies that could 
reduce metastatic potential. Here, we review the 
current knowledge regarding BMPs role in breast cancer 
progression, metastasis and relapse.
BMP signalling aberrations in breast cancer
BMP signalling pathway
BMPs are members of the TGF-β super family, which 
regulate cellular differentiation, proliferation, apoptosis 
and motility, particularly in embryonic development and 
tissue homeostasis (Nohe et al. 2004, Ye et al. 2009, Davis 
et  al. 2016). Binding to a complex of serine-threonine 
kinase transmembrane receptors comprising Type I and 
Type II receptors induces intracellular signalling through 
the pathway-restricted Smads (R-Smads-Smads 1, 5 and 8) 
and Smad-4, which assists the translocation into nucleus, 
thus regulating BMP responsive genes in association 
with transcriptional co-activators or co-repressors. This 
pathway is known as the Smad dependent or canonical 
pathway. In noncanonical BMP signalling, the receptor 
complex is instead recruited as a result of ligand binding, 
triggering a Smad-independent pathway, which involves 
various branches of the mitogen-activated protein kinase 
(MAPK) pathway, RAS pathways, PI3K/Akt pathways, P/KC 
pathways and Rho-GTPases pathways, dependant on both 
the BMP ligand and receptors recruited (Derynck & Feng 
1997, Nohe et al. 2004, Ye et al. 2009, Bragdon et al. 2011, 
Davis et al. 2016). As a vital embryonic pathway, several 
layers of inhibition and control are important for normal 
tissue development and add further to the great plasticity 
of BMP signalling (Fig. 1).
Regulation of BMP signalling
BAMBI (BMP and activin membrane bound inhibitor) 
is a pseudoreceptor related to type I receptors, which 
limits BMP function. It is present in breast cancer cell 
lines and expression has been noted as upregulated in 
cancers, but as it also abrogates TGF-β signalling, the 
pro-oncogenic effect may not be speciic to BMPs (Wang 
2015). I-Smads (inhibitory Smads) such as Smad 6 and 7 
Figure 1
BMP signalling utilises canonical Smad dependant 
pathways and non-canonical Smad-independent 
pathways. According to combination and 
sequence of receptor complex formation or 
recruitment if the BMP ligand (two tone sphere) 
binds to a preformed heteromeric receptor 
complex this results in Smad dependant 
signalling. The Smad 1/5/8 complex binds to Smad 
4 and translocates to the nucleus whereby they 
interact with transcription factors, or directly 
binding to DNA to regulate gene transcription. If 
the BMP binds to a type I receptor and recruits 
the type 2 receptor to the complex, Smad-
independent signalling results. There are multiple 
levels of regulation, including inhibitory Smads 6 
and 7 (I-Smads), pseudoreceptors lacking the 
serine/threonine kinase domain (BAMBI), 
ubiquitination and degradation (Smurf/Nedd4/
RNF11) and target gene transcription of negative 
regulators (such as the BMP antagonists) 
functioning as negative feedback. There are 
myriad other BMP target genes in breast cancer 
such as ID1, Snail, Zeb1, p21, PTEN, MMPs and ER 
that affect cancer cell functions. The igure was 
made with pathway builder tools from www.
proteinlounge.com. A full colour version of the 
igure is available at http://dx.doi.org/10.1530/
ERC-17-0139
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prevent complex formation between R-Smads and 
Smad-4, thus affecting transcriptional regulation in the 
nucleus, which was well reviewed previously (Miyazono 
2008, Bragdon et  al. 2011). They bind to activated 
type I receptors blocking activity and promoting 
the degradation of receptors through ubiquitination 
pathways (Nohe et al. 2004).
Smad ubiquitination regulatory factor 1 (Smurf1) is 
the ligase of Smad 1/5/8, amongst other substrates. In turn, 
Smurf2 induces degradation of Smurf 1. Downregulation 
of Smurf1 in breast cancer MDA-MB-231 cells impaired 
migration (Xie et al. 2013) whereas Smurf 2 knockdown 
in these cells resulted in enhanced migration in vitro and 
metastasis in vivo (Jin et al. 2009). The ubiquitin ligase 
ring inger protein 11(RNF11) interacts with Smurf1 & 
2, Smad 4 and other ubiquitin ligases to modulate BMP 
signalling pathways and both mRNA and protein have 
been found at high levels in breast tumours (Azmi & 
Seth 2005).
Further regulation is provided by secreted extracellular 
BMP antagonists (Walsh et  al. 2010). BMP antagonists 
can block the binding of BMPs to their receptors by 
directly binding to the BMP ligands. These antagonists 
are often BMP transcription target genes, forming an 
important regulatory feedback loop for normal tissue 
development (Alarmo & Kallioniemi 2010). In developing 
breast epithelium, the interplay between BMPs 2 and 4 
and antagonist Noggin is essential for normal ductal 
elongation and myoepithelial compartmentalisation 
(Cowin & Wysolmerski 2010, Forsman et  al. 2013). 
Noggin, Chordin and Gremlin appear to be upregulated 
(but not mutated) in breast cancer, but their potential role 
in breast tumourigenesis has not been well studied and 
in other cancers they are both pro and anti-tumourigenic 
(Walsh et al. 2010, Owens et al. 2015). Finally, Betaglycan 
(TGF-β receptor III) binds BMPs 2, 4, 7 and GDF5, helping 
to mediate BMP signalling. Its expression in breast cancer 
models suppresses BMP-induced invasion and migration 
through ligand sequestration when in soluble form (Gatza 
et al. 2014).
BMP signalling is heterogeneous and complex, 
with multiple regulatory inluences that are currently 
implicated in breast cancer, but not yet fully elucidated.
BMPs in breast tumourigenesis
Inluence of BMPs in cell cycle and proliferation
BMPs are able to regulate the growth of breast cancer cell 
lines (Table  1). BMP-2, BMP4, BMP-6, BMP-9, BMP-10, 
BMP-15 and GDF9a impede the proliferation of breast 
cancer cells (Hanavadi et al. 2007, Du et al. 2008, Alarmo 
& Kallioniemi 2010, Ye et  al. 2010, Ren et  al. 2014a). 
Inhibition of BMP signalling dramatically downregulates 
protein levels of mitotic checkpoint components 
BUB3, Hec1, TTK and MAD2, leading to cell division 
Table 1 BMP in breast cancer.
 Expression in breast cancer Function in breast cancer cells Effect in vivo
 Primuary tumour Bone metastases Proliferation Apoptosis Motility EMT Primary Bone
BMP-2 ↓/↑  ↓ ↓/↑ ↑ ↑ ↑ ↑
BMP-4 ↑  ↓/↑  ↓/↑ ↑ ↓/↑  
BMP-5 ↑        
BMP-6 ↓/↑  ↓ ↓ ↓ ↓   
BMP-7 ↓/↑ ↓/↑ ↓/↑  ↑ ↓ ↓ ↓
GDF9A ↓  ↓  ↓    
BMP-9   ↓ ↑ ↑  ↓ ↓
BMP-10 ↓  ↓  ↓    
BMP-15 ↓  ↓  ↓    
BMPR-IA  ↑ ↑  ↑ ↓/↑ ↑ ↑
BMPR-IB ↓/↑  ↓  ↑    
BMPR-II ↑  ↑  ↓    
NOGGIN  ↑      ↓
Expression of BMPs in breast cancer shown in the table are based on literature: BMP-2 (Soda et al. 1998, Clement et al. 2000, Ghosh-Choudhury et al. 
2000a,b, Pouliot & Labrie 2002, Reinholz et al. 2002, Clement et al. 2005, Raida et al. 2005a, Katsuno et al. 2008); BMP-4 (Alarmo et al. 2007, 2013, 
Ketolainen et al. 2010, Guo et al. 2012, Ampuja et al. 2013, 2016, Owens et al. 2013, Cao et al. 2014); BMP-5 (Bobinac et al. 2005, Davies et al. 2008); 
BMP-6 (Clement et al. 1999, Yang et al. 2007, 2009, Du et al. 2008, 2009, Lian et al. 2013, Hu et al. 2016); BMP-7 (Schwalbe et al. 2003, Alarmo et al. 2006, 
2007, 2008, 2009, Buijs et al. 2007, Sakai et al. 2012); GDF9A/BMP-15 (Hanavadi et al. 2007); BMP-9 (Wang et al. 2011, Ren et al. 2014a,b); BMP-10 
(Ye et al. 2010); BMPR-IA (Katsuno et al. 2008, Pickup et al. 2015a); BMPR-IB (Helms et al. 2005, Bokobza et al. 2009, Allison et al. 2016); BMPR-II 
(Pouliot et al. 2003, Owens et al. 2012); Noggin (Tarragona et al. 2012). Up arrows indicate upregulated (expression) or promote (function and effect), 
whilst the down arrows indicate downregulated (expression) or inhibit (function and effect).
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and tumourigenesis, whereas an upregulation of BMP 
signalling has the converse effect in breast cancer cells 
(Yan et al. 2012).
Studies have focused on the effects of BMP-2, which 
has a direct anti-proliferative effect on tumour cells at a 
very high concentration in vitro (Soda et al. 1998). A kinase 
inactive type II TGF-β receptor (dnTbetaRII) eliminated 
the anti-proliferative effect of BMP-2 in breast cancer cells 
by preventing the phosphorylation of Smad-1 (Dumont 
& Arteaga 2003). Interestingly, Waite and coworkers 
demonstrated that BMP-2 increases PTEN expression 
in MCF-7 cells with resultant decreased proliferation. 
PTEN is a tumour suppressor affecting proliferation by 
modulating the PI3K/Akt pathway. Mutations in PTEN 
are associated with Cowden’s disease, in which there 
is a markedly increased risk of breast carcinoma. In the 
presence of BMP-2, association of PTEN with ubiquitin 
conjugating proteins was reduced, indicating BMP-2 
may decrease PTEN degradation, thus increasing the 
pool of available PTEN and resulting in inhibition of 
cellular proliferation (Waite & Eng 2003). The presence 
and composition of BMP receptor complexes can also 
inluence the effect of BMPs on breast tumourigenesis, as 
although BMPR-IB mediates an inhibition of breast cancer 
proliferation, BMPR-IA (ALK-3) contributes to progression 
of breast cancer at primary and secondary sites (Katsuno 
et al. 2008). BMPR-II promotes BMP-induced proliferation 
in breast cancer cells (Bokobza et  al. 2009) and over-
expression of a dominant negative BMPR-II in T-47D 
breast cancer cells led to an arrest of cancer cells at the G1 
phase of the cell cycle (Pouliot et al. 2003).
With regard to cell cycle, it appears that many BMPs 
have direct and indirect anti-proliferative effect in breast 
cancer, but this may be subject to aberrations in the 
balance or function of BMP receptors.
Inluence of BMPs on apoptosis
BMP-2 under routine culture conditions, shows pro-
apoptotic effect in MCF-7 breast cancer cells, in which 
the expression and function of apoptosis related genes, 
particularly protein kinase R (PKR), and subsequent 
activation of its substrate eIF2α are regulated by BMP 
signalling (Steinert et  al. 2008). In MDA-MB 231 cancer 
cells, overexpression of Neogenin (a co-receptor for 
BMPs) signiicantly increased apoptosis whilst inhibiting 
BMP-2 induced phosphorylation of Smad1/5/8. This 
interesting new player appears to modulate BMP/Smad 
signalling, resulting in the observed effect on apoptosis 
(Zhang  et  al.  2015). The exact mechanism is not yet 
known, but Neogenin forms a complex with repulsive 
guidance molecules (RGM) (Bell et  al. 2013), such as 
RGMB, which are also co-receptors for BMP signalling. 
In MDA-MB-231 cells, knockdown of RGMB promoted 
survival, reduced Caspase 3 expression and promoted 
growth and migration via regulation of Smad dependant 
and independent BMP signalling (Li et al. 2012).
However, under different experimental conditions, 
without supplement of serum, BMP-2 increases the 
resistance of MCF-7 breast cancer cells to hypoxia-
induced apoptosis, via the activation of both the 
MAPK pathway and ID-1, and suppression of Caspase-3 
(Clement et  al. 2000, Raida et  al. 2005a). The other 
example is BMP-6, which inhibits proliferation through 
an upregulation of miRNA-192 and resultant repression 
of cell cycle progression in MDA-MB-231 cells (Du et al. 
2008). However, under deprivation of serum, BMP-6 
protects MDA-MB-231 cancer cells from stress-induced 
apoptosis through upregulation of survivin, via the Smad 
dependent pathway, and activation of p38 via the Smad-
independent pathway, with both contributing to the anti-
apoptotic effect of BMP-6 (Du et al. 2008).
It appears with regard to apoptosis in breast cancer 
that BMPs may have a dual role dependent on cellular 
conditions, being pro-apoptotic unless under conditions 
of cellular stress. However, the evidence from in vitro 
study warrants further exploration for their possible role 
in therapeutic resistance.
Expression of BMPs and clinical correlations
In clinical breast cancer samples, decreased mRNA 
expression of BMP-2, BMP-7, BMP-10 and GDF-9a (an 
analogue of BMP-15/GDF-9b) were seen and associated 
with poor clinical outcomes (Reinholz et al. 2002, Buijs et al. 
2007, Hanavadi et al. 2007, Davies et al. 2008, Ye et al. 2010). 
In contrast, BMP-2, BMP-4, BMP-5 and BMP-7 expression 
has been reported as elevated in breast tumours and the 
latter two associated with poor prognosis (Bobinac et al. 
2005, Raida et al. 2005a, Alarmo et al. 2006, 2007, Davies 
et al. 2008). The key may be that BMPs have bidirectional 
actions in breast cancer, such as BMP-4, which not only 
suppresses breast cancer cell growth, but also promotes 
invasion and migration. Immunohistochemistry studies 
associated BMP-4 expression with low proliferation 
tumours, but also increased recurrence (Alarmo et  al. 
2013). Interestingly, this may be supported by the inding 
of increased transcript levels of BMP-4 and its receptor 
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BMPRII in the peripheral blood of breast cancer patients 
in advanced disease (Gul et al. 2015). Another potentially 
bidirectional BMP, both increased and decreased BMP-7 
expression in primary breast tumours has been correlated 
with disease-speciic bone metastases (Buijs et  al. 2007, 
Alarmo et al. 2008).
The difference in indings from clinical samples may 
relect the heterogeneity of breast cancer and the crosstalk 
of BMP signalling with a variety of other signalling 
pathways critical in breast tumourigenesis.
BMPs and clinical subtypes of breast cancer
It has become clear that breast cancers are heterogeneous, 
with distinct subtypes based on molecular proile (Cancer 
Genome Atlas Network 2012), and clinically, treatments 
are increasingly directed toward molecular markers such 
as the hormone receptors. The development of hormonal 
therapies conirmed a distinction in behaviour between 
oestrogen receptor (ER)-positive and ER-negative breast 
cancers. Tamoxifen was initially used as a treatment for 
all breast cancers, but it later became apparent that only 
those tumours expressing hormone receptors beneit. 
The introduction of trastuzumab (Herceptin) has also 
introduced tumour proiling of HER2 expression as a 
standard in clinical care. More recently, gene expression 
proiling has made its way into the clinic to predict those 
with early breast cancer at risk of relapse that would 
beneit from chemotherapy. Receptor status appears to 
inluence the effect of BMP signalling as seen in clinical 
studies and several in vitro studies, which could make 
BMP/BMPR status another important proiling marker.
BMPs and oestrogen receptor signalling
Oestrogen regulates the expression of BMPR-IA, BMPR-IB, 
ActRIIA and ActRIIB, but has no effect on the expression 
of ActR1 and BMPR-II (Takahashi et  al. 2008). Elevated 
expression of BMPR-IB was associated with high tumour 
grade, high tumour proliferation, cytogenetic instability 
and a poor prognosis in ER positive carcinomas (Helms 
et al. 2005). A decreased level of BMPR-IB associated with 
poor prognosis in a majority of ER-negative tumours 
(Bokobza et al. 2009).
The expression of BMP-7 highly correlates with 
the expression level of ER, although BMP-7 expression 
reduces in response to oestrogen (Schwalbe et  al. 
2003, Alarmo & Kallioniemi 2010). BMP-2 expression 
is signiicantly higher in the ER-negative tumours 
(Julien et al. 2011). Silencing of ERα results in resistance 
to effects of oestradiol increased BMP-2 expression, and 
genetic changes associated with epithelial–mesenchymal 
transition (EMT) (Al Saleh et  al. 2011). BMP-6 mRNA 
has been declared both increased and reduced in 
comparison with non-tumour margins (Clement 
et  al. 1999). Studies show over-expression of BMP-6 
particularly in ER positive cell lines and tumour samples 
(Ong et  al. 2004, Zhang et  al. 2007), however, BMP-6 
inhibits oestrogen-induced mitosis of ER positive breast 
cancer cells (Takahashi et al. 2008) and targeting BMP-6 
in MCF-7 cells using shRNA knockdown promoted cell 
proliferation (Lian et al. 2013).
The mechanism of these interactions is being 
explored. BMP-6 appears to be activated in a dose- 
dependant manner by oestrogen through interaction of 
ER with sites on the BMP-6 promoter region (Zhang et al. 
2005). In addition, BMP-6 promoter methylation status 
correlates with ER status in breast cancer. Methylation of 
the BMP-6 gene promoter has been detected in ER-negative 
MDA-MB-231 cells; whereas in ER positive MCF-7 and 
T47D, the BMP-6 gene promoter remains demethylated. 
In 33 breast tumour specimens, hypermethylation of 
BMP-6 was observed in all ER-negative cases whereas 
lower methylation frequency was observed in ER positive 
cases (Zhang et al. 2007).
Oestrogen interferes with the biological function 
of BMP-2 by inhibiting the activation of Smad, as a 
result of biochemical interaction between Smad and 
ERα (Yamamoto et  al. 2002). Smad-4 can associate with 
cytoplasmic ERα, preventing the transcriptional regulation 
mediated by ERα (Wu et al. 2003). In MDA-MB-231 cells 
BMP-2 treatment induced the expression of a splicing 
variant of ER (ERα-36) in a dose-dependent manner, and 
growth of MDA-MB-231 cells could be stimulated by 
oestradiol, even though they were insensitive to it before 
BMP-2 induction. When the BMP-2 signalling pathway 
was silenced by si-BMPRIA and si-BMPRIB, the ERα-36 
induction was eradicated (Wang et al. 2012).
In a bidirectional manner, BMPs as well as being 
affected by ER signalling can in turn have an effect on ER 
signalling. BMP-2 inhibits oestradiol-induced proliferation 
of breast cancer cells, via upregulation of cyclin kinase 
inhibitor p21, which in turn inhibits the oestradiol-
induced cyclin D1-associated kinase activity (Ghosh-
Choudhury et al. 2000a). The Smad dependent signalling 
is indispensable for BMP-2 induced p21 expression and 
the consequent inhibitory effect on cell proliferation 
(Pouliot & Labrie 2002).
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It is evident that the ER status has a bearing on the 
cells’ response to BMPs and vice versa, at both nuclear 
and cytoplasmic level, involving signalling cross talk and 
transcriptional regulation. Once again it is likely that the 
resultant inluence on breast tumours and their response 
to hormonal therapies depend on the balance of these 
interactions between the signalling pathways.
BMPs and other signalling crosstalk
Co-regulation of the growth of breast cancer cells can 
occur between the BMP and other cell signalling pathways. 
This includes other members of the TGF-β super family 
(Katsuno et  al. 2008), epidermal growth factor (EGF) 
(Schwalbe et  al. 2003), hepatocyte growth factor (HGF) 
and HGF receptors (Imai et al. 2005, Ye et al. 2007a, 2008) 
and Wnt signalling (Guo & Wang 2009).
The upregulation of p21 by BMP-2 prevents EGF-
induced proliferation of MDA-MB-231 breast cancer cells 
(Ghosh-Choudhury et  al. 2000b). This may relect why 
MDA-MB-231, an ER-negative tumour cell line, responds 
to recombinant human BMP-2 with a more signiicantly 
reduced proliferation, in comparison with the ER positive 
MCF-7 cells (Arnold et al. 1999).
BMP-4 is considered as an inhibitor of breast cancer 
cell growth, but can also have a synergistic effect on 
proliferation of breast cancer cells induced by ibroblast 
growth factor (FGF), EGF and HGF (Montesano et al. 2008). 
EGF treatment of breast cancer cells in vitro upregulated 
BMP-4 signalling via the Smad pathway, leading to 
suppression of matrix metalloprotease (MMP) 9. This 
suppression was attenuated with an addition of BMP-4 
antagonist Gremlin or Smad 6 (Laulan & St-Pierre 2015). In 
addition, BMP-6 in breast cancer cells can be upregulated by 
EGF and other EGFR ligands such as transforming growth 
factor-α, amphiregulin and betacellulin (Clement et  al. 
1999). Conversely, EGF, FGF and HGF activated MAPK/
ERK results in a phosphorylation of the linking region 
of Smad1/5/8 leading to a reduced nuclear translocation 
and a suppression of BMP target genes (Kretzschmar et al. 
1997, Guo & Wang 2009). BMPs exert reciprocal effects, 
suppressing EGF-induced gene transcription through 
MAPK/ERK-1 signalling (Ghosh Choudhury et  al. 1999). 
BMP-9 inhibits the proliferation and metastasis of SK-BR-3 
breast cancer cells via decreasing HER2 expression and 
inactivating ERK1/2 and PI3K/AKT signalling pathways 
(Ren et al. 2014a).
SOSTDC1, a secreted regulator of both BMP and Wnt 
signalling pathways, is under expressed in breast cancer 
and can differentially affect signalling induced by Wnt3a, 
BMP-2 and BMP-7. In breast cancer cells, SOSTDC1 
modestly increases Wnt3a signalling, decreases BMP-7 
signalling, whilst eliciting little effect on BMP-2-induced 
signalling (Clausen et al. 2011).
This highlights the important inluence of other 
signalling pathways and the canonical or noncanonical 
BMP signalling pathways, and may be one of the reasons 
for the varied and sometimes contradictory study 
outcomes regarding BMPs in breast cancer.
BMPs and the androgen receptor
More recently androgen receptor status has become a focus 
of research, particularly in relation to treatment resistance. 
Reported as either tumour suppressor or promoter, 
its expression has been linked to both good and poor 
prognosis (Feng et al. 2017). In ER positive tumours that 
respond to neoadjuvant endocrine therapy, AR mRNA and 
protein expression decreases, whereas in tumours those 
fail to respond, AR mRNA does not decrease. AR over-
expression increases tamoxifen resistance in breast cancer 
models in vitro and in vivo. In a clinical cohort, a high AR: 
ER ratio was shown as an independent risk for failure of 
tamoxifen treatment and poor survival (Cochrane et  al. 
2014).
Upon an ERK-mediated phosphorylation, BMP-
activated Smad1 can bind to AR leading to an inhibition 
of AR-induced transcription and its corresponding effect 
on cellular functions of prostate cells (Guo & Wang 2009). 
It is not yet known whether similar interactions between 
BMP signalling and AR are found in breast cancers, and 
this would be a novel area of exploration and possible 
targeted therapy for endocrine treatment resistant breast 
cancers.
BMPs and progression of breast cancer
BMPs in epithelial–mesenchymal transition (EMT)
EMT is an important event during the development and 
progression of cancer, causing disruption of epithelial 
homeostasis that may lead to carcinogenesis; it can 
also transform the indolent tumour cells into a more 
aggressive colony, leading to metastasis (Larue & Bellacosa 
2005, Lamouille et al. 2014). The early steps of metastasis, 
such as invasion and extravasation are facilitated by cells 
acquiring mesenchymal traits, however, the ability to 
colonise distant tissues and form macroscopic metastases 
may be facilitated more by epithelial properties, and thus 
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the breast cancer cell at any one time may be triggered 
towards either EMT or MET by differential BMP signalling.
EMT regulated by BMPs has been implicated in 
foetal and postnatal development of different organs 
and tissues, including mammary gland development, 
where BMP-2 and 4 have essential roles in both epithelial 
and mesenchymal differentiation (Nakajima et al. 2000, 
Romano & Runyan 2000, Hens & Wysolmerski 2005).
In vitro, BMP-4 subverts the ability of mammary 
epithelial cells to form polarized lumen-containing 
structures, and also endows them with invasive properties, 
demonstrating a direct effect promoting a mesenchymal 
phenotype (Montesano 2007). TGF-β and BMP-2 
signalling in murine mammary cancer cell lines results 
in transcription of genes that suppress the epithelial 
phenotype. miR-200 counteracts this by targeting the 
BMP-2 downstream transcription factors responsible for 
epithelial gene repression, such as Crtap, Fhod1, Smad2, 
Map3k1, Tob1, Ywhag/14-3-3γ, Ywhab/14-3-3β, Smad5, 
Zfp36, Xbp1, Mapk12 and Snail (Perdigao-Henriques 
et  al. 2016). BMP-2 appears to promote motility and 
invasiveness of MCF-7 and MDA-MB-231 cells, both in 
vitro and in vivo (Clement et al. 2005, Katsuno et al. 2008). 
BMP-2 upregulation of target gene ID-1 (which activates 
pathways involved in tumour progression) may contribute 
to this effect (Gautschi et al. 2008) (Fig. 2).
BMP receptors are also important in EMT, with 
application of a type I BMPR inhibitor to mice reducing 
key EMT-related genes such as Snail, Twist, Zeb1 and Zeb2 
(Balboni et al. 2013, Owens et al. 2015). In humans, high 
BMPRIA expression correlates with poor survival (Pickup 
et  al. 2015a). Knockdown of BMPRIA in vivo delayed 
tumour onset, and also subsequent growth of tumours 
and improved survival, despite conversely seeming to 
induce EMT-like tumour transitions, such as increased 
Vimentin (Pickup et al. 2015a).
Not all BMPs induce EMT, and some appear to promote 
MET, reducing the aggressive properties of tumour cells. In 
murine mammary epithelial cells (NMuMG), BMP-7 was 
not able to induce EMT whereas TGF-β1 could (Piek et al. 
1999). BMP-7 is able to increase cytokeratin expression, 
and decrease vimentin in breast cancer cells in vitro and 
in vivo, leading to an epithelial-like phenotype (Buijs et al. 
2007). This effect is also seen with BMP 6, which restores 
E-cadherin-mediated cell-to-cell adhesion and prevents 
breast cancer metastasis through the downregulation of 
miR-21 and δEF1 (ZEB1, whose expression associates with 
invasive breast cancer phenotype) (Yang et al. 2007, Du 
et al. 2009, de Boeck et al. 2016).
BMPs effect on tumour microenvironment, 
migration and invasion
Tumour microenvironment and the interaction between 
tumour cells and surrounding support cells are important 
for the progression and invasion of tumours (Fig.  2). 
Stimulation of ibroblasts by BMP signalling can promote 
breast tumour cell invasion and increased inlammatory 
Figure 2
BMPs mediate crosstalk between breast cancer 
cells and microenvironment during disease 
progression. BMP signalling by tumour-associated 
stromal cells (or cancer associated ibroblasts) 
alter the expression of EMT-related genes in 
breast cancer cells such as ZEB1, with BMP-2 and 4 
in particular, promoting the mesenchymal 
phenotype. Likewise, breast cancer cells secreting 
BMP-2 and 4 can stimulate ibroblasts to produce 
chemokines and enzymes (Tenascin W, MMPs) 
that promote invasion and motility. Breast cancer 
cells are then able to disseminate to bone via 
lymphovascular invasion. However, there are 
BMPs that reduce invasion (BMP-6, BMP-10, 
BMP-15) and others who have a dual or 
bidirectional role dependant on cellular context, 
such as BMP-4. The igure was created using 
Servier Medical Art tools http://servier.com. A full 
colour version of the igure is available at  
http://dx.doi.org/10.1530/ERC-17-0139
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cytokine production (Owens et al. 2012). Loss of BMPRII 
in murine ibroblasts promoted tumour metastasis and 
sustained inlammatory cell iniltration (Pickup et  al. 
2015b). This suggests BMPRII can have both direct 
suppressive effects on tumour cells, but also indirectly 
via regulation of inlammation in the tumour-associated 
stroma (Owens et al. 2012, Pickup et al. 2015b).
In triple negative MDA-MB-468 cells, upregulated 
BMPRIB showed increased migratory capacity in 
response to BMP-2, which was abrogated by the BMPR 
antagonist dorsomorphin (Allison et  al. 2016). An 
analogue of dorsomorphin (DMH1), much more highly 
selective for type 1 BMPR, can attenuate the pro-tumour 
microenvironment by altering the expression of certain 
genes (such as ID-1 and matrix metalloproteases-MMPs) 
in ibroblasts, lymphatic vessels and macrophages in a 
mouse model (Owens et al. 2015).
BMP-2 may contribute to the invasiveness of 
tumour cells via induction of the extracellular matrix 
glycoprotein Tenascin-W in the tumour-surrounding 
stroma. Smad-independent signalling through p38 
and JNK pathways is involved in BMP-2 induction of 
Tenascin-W and overexpression of Tenascin-W in the 
stroma of breast cancer promotes invasion and migration 
of cancer cells through an interaction with α8 integrin 
(Scherberich et al. 2005).
Treatment with BMP-4 increased invasion and 
migration in both breast cancer cell lines and a mouse 
model (Ketolainen et  al. 2010, Guo et  al. 2012, Ampuja 
et  al. 2013, 2016). CCN6 is an extracellular matrix 
associated protein that has been shown in vitro and in vivo 
to directly antagonise this BMP-4 mediated invasiveness 
and metastases (Pal et al. 2012). A similar effect to BMP-2 
on stromal cells appears to be true with BMP-4 treatment 
in mammary stromal ibroblasts. Fibroblasts stimulated 
with BMP-4 enhanced MCF-7 cell invasion, and these 
effects were inhibited by DMH1. BMP-4 increased MMP-3 
and IL-6 in conditioned medium from treated mammary 
ibroblasts, suggesting BMP-4 can inluence the tumour 
microenvironment to promote breast cancer invasion 
(Owens et al. 2013).
Interestingly, BMP-4 inhibits aggressiveness 
in different breast cancer cell lines under different 
experimental conditions. Overexpression of N-myc 
downstream-regulated gene 2 (NDRG2) in MDA-MB-231 
cells induced BMP-4 and inhibited expression of MMP-
1, -3 and -9 compared to control. When BMP-4 was 
neutralised with anti-BMP-4 antibody, MMP-9 expression 
recovered and migratory capacity of the cells increased. 
Application of rhBMP-4 to wild type MDA-MB-231 cells 
suppressed MMP-9 expression and activity, reducing 
migration and invasion (Shon et al. 2009). Additionally, 
in a mouse model, BMP-4 suppressed metastasis, 
seemingly by regulating anti-tumor immune responses 
(Cao et al. 2014).
Forced expression of GDF-9a/BMP-15 in breast cancer 
cells also reduced invasiveness in vitro, as does BMP-10 
(Hanavadi et al. 2007, Ye et al. 2010). Hu and coworkers 
showed that BMP-6 markedly downregulated matrix 
metalloproteinase-1 (MMP-1) expression at both the 
mRNA and protein levels in MDA-MB231 cells, inhibiting 
invasion, and this effect was signiicantly attenuated by 
overexpression of MMP-1. BMP-6 also increased adhesion 
and cell-cell contacts in these cells (de Boeck et al. 2016, 
Hu et al. 2016).
The above experimental evidence suggests that BMPs 
can differentially inluence tumour invasion by regulating 
the balance of MMPs, extracellular matrix components, 
cytokines and immune or inlammatory cells in the 
tumour microenvironment.
BMPs and angiogenesis in breast cancer
Tumour angiogenesis has been shown to be important 
in breast cancer progression and metastasis (Ribatti et al. 
2016) and current knowledge regarding the role of BMPs 
and angiogenesis has been well reviewed here (Ye & Jiang 
2016) (Fig. 3). In general, experimental evidence suggests 
that BMPs promote angiogenesis indirectly through 
upregulation of the expression of vascular endothelial 
growth factor (VEGF) (Yeh & Lee 1999, Deckers et al. 2002, 
Dai et al. 2004).
Regarding breast cancer speciically, one study has 
reported that BMP-2 promotes breast tumour related 
angiogenesis through stimulating p38 MAPK pathway 
and ID-1 expression (Raida et  al. 2005b). Conversely, 
Chi and coworkers demonstrated overexpression of BMP 
antagonist Coco (DAND5) in breast cancer cells promoted 
micro-vascular formation in vitro and in mouse xenograft 
tumours, although the mechanism has not been clariied. 
They also found Coco positivity in breast cancer patient 
serum correlated with relapse and poor survival, although 
this could be due to its inluence on other aspects of 
tumour progression (Chi et  al. 2016). Current ongoing 
clinical trials are examining the effect of BMP-9 and 10 
blocking agents as anti-angiogenic treatments for solid 
tumours, which is further addressed below. The limited 
literature regarding BMPs in breast tumour angiogenesis 
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makes this a rich area for study, particularly considering 
the potential therapeutic applications.
BMPs and dissemination of breast cancer 
to bone
BMPs and the bone environment
A now traditional view of cancer metastasis is Paget's 
‘seed and soil’ hypothesis, namely that the cancer 
cell will deposit and grow only if the environment is 
favourable towards that cancer cell, i.e., both the seed 
and the soil have to be mutually compatible. Bone 
metastasis involves cancer cell dissemination from the 
primary tumour, extravasation into the blood stream 
and occupation of the bone marrow space. As vital 
regulators of bone formation, BMPs have been of great 
interest in this ield with several studies examining their 
role in bone metastases. In normal bone physiology and 
turnover, BMP signalling is essential for differentiation 
of mesenchymal stem cells (MSCs) and maturation 
into chondroblasts and osteoblasts, resulting in bone 
formation. BMP-2, BMP-4, BMP-6, BMP-7, BMP-9, BMP-
12 and BMP-13 induce MSCs differentiation, but not 
all are osteoinductive in nature (Alarmo & Kallioniemi 
2010, Carreira et al. 2014). BMPs also induce osteoblasts 
to produce certain factors inluential to osteoclast 
maturation and function. Thus, BMPs are an integral 
part of the bone environment (Alarmo & Kallioniemi 
2010, Rahman et al. 2015).
Aberration in BMPs and bone metastasis
In breast cancer, BMP-induced transcriptional 
pathways are active in bone metastatic lesions in vivo 
and dominant negative BMP receptors reduced bone 
metastases in vivo (Katsuno et  al. 2008). Decreased 
expression of BMP-7 in primary tumours correlates 
with bone metastases and BMP-7 is able to inhibit the 
growth of breast cancer tumours in bone in vivo (Buijs 
et al. 2007). Conversely, other studies have shown BMP-7 
overexpression in primary tumours associated with bone 
metastases (Alarmo & Kallioniemi 2010). In murine 
4T1E/M3 mammary cells, which are highly metastatic to 
bone, expression of BMP-7, BMPR and phosphorylated 
Smad1/5/8 is upregulated. These highly invasive features 
are attenuated when BMP-7 is inhibited (Sakai et  al. 
2012). BMP-9 inhibits the growth of breast cancer cells 
in vitro and in vivo, and also suppresses the growth of 
tumour cells in bone (Wang et al. 2011, Ren et al. 2014b). 
Downregulation of connective tissue growth factor 
(CTGF) by BMP-9 is involved in the inhibition of tumour 
growth in bone (Ren et al. 2014b).
Breast cancer cells themselves can acquire an 
osteoblast-like phenotype, by ectopically expressing 
bone matrix proteins such as bone sialoprotein (BSP), 
osteopontin (OPN), osteoprotegerin (OPG) and 
osteoblast-speciic cadherins (Ibrahim et al. 2000, Kapoor 
et al. 2008, Tan et al. 2016). Tan and coworkers (Tan et al. 
2016) showed that breast cancer cells with induced EMT 
exhibited an elevated level of bone-related genes (BRGs) 
Figure 3
It has been demonstrated that BMP-2, -4, -6, -7, 
and GDF5, are capable of directly inducing 
angiogenesis in vascular endothelial cells, whilst 
effect of BMP 9/10 seems more context 
dependent. BMP-9 has biphasic effects on 
endothelial cells. High doses can inhibit 
endothelial proliferation and migration, whereas 
low doses can have stimulatory effects. Indirectly, 
BMPs can act on stromal cells to promote the 
secretion of pro- angiogenic factors such as VEGF. 
This can be attenuated by BMP antagonism such 
as Noggin attenuating the pro-angiogenic effect 
of BMP 7. Another BMP antagonist, gremlin has a 
BMP independent function promoting 
angiogenesis by interaction with VEGF receptors. 
The igure was created using Servier Medical Art 
tools http://servier.com. A full colour version of 
the igure is available at http://dx.doi.org/10.1530/
ERC-17-0139
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and osteoblast-like features in an exposure to BMP-2. 
Breast cancer cells expressing these BRGs preferentially 
metastasise and survive in bone. It also interestingly made 
cells more resistant to chemotherapy. These effects were 
reversed with Noggin application, or knockdown of runt-
related transcription factor 2 (RUNX2), which regulates 
bone remodelling, and osteogenic differentiation (Alarmo 
& Kallioniemi 2010, Carreira et al. 2014, Tan et al. 2016). 
This osteomimicry induced by BMPs may be one of 
the reasons breast cancer cells home to bone tissue and 
survive in the bone microenvironment (Rucci & Teti 
2010). In other words, BMP signalling in breast tumours 
could create a subset of bone-speciic metastatic cells: the 
right kind of ‘seed’ for a speciic soil.
Regulators of BMP signalling in bone metastases
BMPs and their antagonists can also inluence the bone 
microenvironment, for example, orthotropic implant of 
silk scaffolds carrying BMP-2 showed increased metastatic 
spread of breast cancer cells to bone in vivo (Moreau 
et  al. 2007). Conditioned medium (CM) from HT-39 
breast cancer cells promoted osteoblastic behaviour in 
osteoprogenitor cells. This effect was blocked by addition 
of Noggin (Bunyaratavej et al. 2000). High expression levels 
of Noggin are associated with bone metastases in both cell 
line/murine models and clinical samples of breast cancer 
bone metastases (Tarragona et  al. 2012). Upregulation 
of Noggin and Follistatin by ZEB1 in breast cancer cells 
induced differentiation of osteoclasts in vitro, suggesting 
an osteolytic inluence in the bone microenvironment 
(Mock et al. 2015), however the role BMP antagonists play 
in coordinating the osteoblastic and osteolytic activities 
in bone metastatic lesions are far from being clear.
Regulation of BMP signalling by oestrogen and ER 
may also contribute to osteoblast differentiation and thus 
may inluence the bony metastatic niche. The selective 
estrogen receptor modulator raloxifene increased the 
activity of the BMP-4 promoter in U-2 OS osteoblast-like 
cells. ER-α is thought to be indispensable for this effect on 
the BMP-4 promoter and may be part of the mechanism 
of this agents in reducing both osteoporosis and breast 
cancer risk (van den Wijngaard et al. 2000).
Oestradiol enhances BMP-4-induced expression 
of osteoblastic markers (Runx2, osterix, osteocalcin) 
in osteoprogenitor cells. In contrast, the expression of 
ER-α and endogenous BMP-4 was suppressed by BMP-4 
treatment regardless of the presence of oestrogen, 
implying the presence of a negative feedback loop for 
osteoblast differentiation (Matsumoto et al. 2013).
In osteoblasts, BMP- 6 reporter activity increased with 
anti-oestrogen treatment, and decreased with oestradiol 
treatment, providing evidence that ER regulates BMP-6 
differentially in breast and bone, and ERα-dependent 
pathways (such as BMPs) may inluence skeletal secondary 
formation in breast cancer, which is consistent with the 
previous observation that patients with ER positive breast 
tumours are more likely to develop skeletal metastases 
(Ong et al. 2004).
In summary, BMPs and their regulators, such as BMP 
antagonists or ER signalling, can also result in a bone 
environment receptive and supportive of metastases, 
and inluential in the balance between osteogenesis and 
osteolysis, i.e., they affect the bone ‘soil’ conditions.
BMPs and breast cancer relapse
As a consequence of improvements in breast cancer 
treatments, nearly 80% of women survive at least 10 years 
after their diagnosis (Cancer Research UK 2017). For 
women with triple negative disease there is high risk 
of early recurrence, relecting the aggressive nature of 
this subtype, and the lack of targeted treatments. For 
receptor-positive tumours, the risk of recurrence is lower, 
but continues potentially for decades after diagnosis 
(Yamashita et al. 2016).
Relapse of disease is often attributed to cancer stem 
cells, cells with tumour initiating capacity and the ability 
to evade the effects of chemotherapy by remaining in an 
alive but quiescent or dormant state, only to clinically 
manifest at a later point, causing symptoms and death 
(Oskarsson et al. 2014).
BMPs and breast cancer stem cells
Mammary tissue inevitably contains stem and progenitor 
cells, undergoing cycles of quiescence and proliferation 
throughout mammary development, maturation and 
involution (Woodward et al. 2005). Stem cells share many 
of the characteristics of cancer cells, including the ability 
to proliferate through a process of self-renewal and a loss 
of contact inhibition and BMPs seem to play a role in 
stem cell and progenitor determination.
BMP-2 enhanced production of luminal progenitors 
in MCF10A mammary cells, whereas BMP-4 prevented 
differentiation. BMP-4 redirected these cells towards an 
immature progenitor phenotype, suggesting a balance 
between BMP-2 and BMP-4 deines mammary cell fate 
(Clement et al. 2017).
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In studies with human embryonic stem (hES) 
cells, BMPs promote differentiation, dependent on the 
feeder cells on which the hES are grown and in the 
context of other signalling pathways. For example, 
in the presence of FGF signalling BMP induces hES 
cells to differentiate into the trophoblast lineage. 
In the presence of FGF and BMP antagonist Noggin, 
hES cells can be maintained in the pluripotent state. 
This implicates the balance of BMP and antagonists 
in the switch between states of self-renewal and 
differentiation (Varga & Wrana 2005).
In breast cancers, the inluence of BMP signalling 
on stem cell populations is not yet clear, and varies 
dependant on experimental conditions. A BMP2/7 
heterodimer strongly reduced the size of a breast cancer 
stem cell population in vitro, and in vivo was able to 
inhibit formation of bone metastases (Buijs et al. 2012). 
Conversely, in separate studies, a BMPR inhibitor 
reduced stem cell populations and clonogenic capacity 
in established mammary epithelial cell lines and primary 
murine tumor cells (Balboni et al. 2013).
Autocrine BMP-4 signalling maintained the stem cell 
phenotype of an A17 invasive mesenchymal cell line, 
whereas BMP-4 inhibition by dorsomorphin resulted in 
epithelial-like traits, by downregulating Snail and Slug 
transcription factors, resulting in loss of stem-features 
and self-renewal ability (Garulli et al. 2014). It may be that 
differential BMPs and receptor proiles in autocrine and 
paracrine signalling result in the variety of effect on breast 
stem cell populations.
BMPs and quiescence
As well as inluencing stem cells, some studies suggest 
BMPs could induce stem cell quiescence, which would 
have important implications for disease relapse. When 
expression of tumour suppressor ΔNp63α was induced in 
MCF-7 cells, the BMP target gene ID-1 was upregulated 
and proliferation signiicantly reduced. There was an 
increase in proportion of progenitor like cells, and cells 
in reversible G0 cell phase. The authors suggest BMP 
signalling induced quiescence in MCF7 cells, mediated by 
ΔNp63α (Amin et al. 2016).
Gao and coworkers demonstrated that paracrine BMP 
signalling suppresses cancer stem cell traits, and that 
BMP antagonist Coco reactivates dormant metastatic 
breast cancer cells in the lungs. Coco induced a self-
renewing stem cell-like phenotype in the metastatic cells 
by blocking the BMP-induced repression of core stem cell 
transcription factors (Gao et al. 2012).
Therapies usually target proliferating cells, thus 
quiescence in disseminated breast cancer cells can result 
in evasion of treatment and disease relapse, potentially 
many years later (Zhang et  al. 2013). BMP signalling 
inluences both self-renewal of cells and the switch 
between active proliferation and quiescence. This is a key 
area for further development in treating, predicting and 
preventing relapse, which remains a signiicant clinical 
challenge in breast cancer.
Implications in breast cancer therapeutics
BMPs are instrumental in the differentiation of bone 
marrow mesenchymal stem cells into bone producing 
osteoblasts in normal bone turnover. BMPs may swing 
the balance between osteolysis and osteogenesis, as 
they promote osteoblast differentiation, which directly 
promotes osteogenesis and is thus the reason recombinant 
BMP-2 is utilised in orthopaedic surgery. But as BMPs 
promote the production of receptor activator of nuclear 
factor kappa-B ligand (RANKL) by osteoblast precursors, 
this indirectly promotes osteoclastogenesis and bone 
resorption. In addition, BMP and Wnt pathways are major 
regulators of normal osteogenesis.
Targeting Wnt/BMP signalling
The Wnt inhibitors sclerostin and dickkopf 1 (DKK1) 
act physiologically as downstream molecules of BMP 
signalling to inhibit canonical Wnt signalling and therefore 
negatively regulate bone mass. Tumour production of 
DKK1 and sclerostin is thought to contribute to osteolytic 
bone lesions (Lipton et  al. 2009, Chen et  al. 2012). 
A DKK1-neutralizing antibody is in clinical trials for 
multiple myeloma, and sclerostin-neutralizing antibodies 
have been developed for osteoporosis. Bortezomib is a 
proteasome inhibitor, which inhibits osteoclast formation 
and bone resorption while enhancing osteoblastic 
differentiation and mineralisation in vitro. The detailed 
mechanism is unclear but may result from decreased 
DKK1. The fact that BMP signalling acts upstream makes 
BMP antagonism and interaction with Wnt signalling a 
future area of exploration for bone metastases therapeutics 
(Lipton et  al. 2009, Suvannasankha & Chirgwin 2014) 
(Fig. 4).
Targeting osteoclast activity
In breast cancer bone metastasis, parathyroid hormone-
related peptide (PTHRP) released from tumour cells 
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up-regulates the expression of RANK-L in preosteoblasts, 
whilst repressing the expression of osteoprotegerin 
(OPG, which normally acts to inhibit RANK-L 
function), leading to a stimulation of osteoclasts and 
consequent bone resorption. Osteoclastic activity in 
turn increases the production of factors that increase 
PTHRP production, including TGFβ, insulin-like growth 
factor (IGF), platelet-derived growth factor (PDGF), and 
BMPs, and this supports the survival of the tumour 
(Suvannasankha & Chirgwin 2014, Yardley 2016). The 
only current treatments for skeletal events in breast 
cancer are focused on inhibiting osteoclast function, 
thus reducing bone resorption. Bisphosphonates bind 
to bone mineral and are then taken up by osteoclasts, 
resulting in apoptosis. Denosumab is a monoclonal 
antibody against RANKL, reducing osteoclast 
differentiation (Steger & Bartsch 2011) (Fig.  4). The 
use of bisphosphonates and denosumab is currently 
a palliative measure, because they have not been 
consistently shown to improve survival or prevent 
bone metastasis. Moreover, breast cancer patients who 
develop pathological fracture have a signiicant 32% 
increased risk of death relative to patients without a 
fracture (Lipton et  al. 2009). Thus, there is a need for 
developing agents that act to prevent bone metastasis, 
and BMPs are under explored in this capacity.
Targeting phosphoinositide-3-kinase-Akt-mTOR pathway
Another area of therapeutic interest more recently is the 
phosphoinositide-3-kinase (PI3K)-Akt-mTOR pathway: a 
key mediator of cellular proliferation, apoptosis, migration 
and angiogenesis, which is commonly activated in breast 
cancer, conferring resistance to hormonal therapy and 
trastuzumab. In lung cancer cells, BMP-2 regulates cellular 
transformation by activating the PI3K/mTOR pathway, 
which was completely inhibited by the mTOR inhibitor 
rapamycin. In breast cancer models, BMP-2 has also been 
shown to induce the proto-oncogene PI3K in osteoblasts 
to regulate differentiation. mTOR blockade suppresses 
RANKL and increases OPG secretion by the bone 
marrow stroma. mTOR inhibitors are part of ongoing 
trials regarding hormone receptor-positive treatment 
resistant tumours, although the apparent involvement 
of PI3K/mTOR in bone makes it of interest for bone 
metastasis (Royce & Osman 2015, Zhang et al. 2016).
BMP speciic inhibitors
The BMP small molecule inhibitors dorsomorphin and 
LDN 193189 reverse stem-like features in breast cancer 
cells and reduce invasiveness, and have been used in 
several breast cancer studies to abrogate BMP signalling. 
Figure 4
BMPs are a vital component of normal bone 
turnover, stimulating the differentiation of 
mesenchymal stem cells (MSC) into osteoblasts, 
which is promoted by oestrogen. Osteoblasts 
secrete RANKL and OPG. If the balance of RANKL is 
higher than its inhibitor OPG, RANKL binds to 
osteoclast precursors and results in their maturation 
and resultant osteolysis. In the vicious cycle of bone 
metastases, tumour cells secrete many factors which 
encourage osteoblast production of RANKL and 
downregulation of OPG, resulting in net osteolysis, 
which further releases factors that support the 
survival and proliferation of the tumour cells. Wnt 
signalling encourages osteoblast maturation and 
OPG secretion. DKK1, downstream of BMP 
signalling, inhibits Wnt signals, and thus tips the 
balance towards osteolysis and reduced bone mass, 
making DKK1 a therapeutic target in osteoporosis 
and osteolytic bone metastases. In the current 
management of osteolytic bone lesions, denosumab 
is a RANKL inhibitor, reducing osteoclast maturation 
and function, whereas bisphosphonates penetrate 
the bone environment, binding to calcium and are 
then taken up by osteoclasts resulting in osteoclast 
apoptosis. The igure was created using Servier 
Medical Art tools http://servier.com.  A full colour 
version of the igure is available at http://dx.doi.
org/10.1530/ERC-17-0139
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However, as yet, have not been advanced towards 
further development for clinical testing in malignancy 
with propensity to metastasise to bone. One agent that 
directly affects BMP signalling and is in clinical trials for 
solid tumours is dalantercept. A soluble chimeric ALK 
1 receptor-like protein (ALK1-Fc), which displays high 
afinity binding with BMP-9 and BMP-10, preventing their 
interaction with the type 1 receptor ALK1. This results in 
inhibition of angiogenesis and suppresses tumour growth 
(Hawinkels et al. 2016) (Fig. 3). Initial studies show ALK1-Fc 
decreased metastasis formation in a breast cancer model 
(Cunha & Pietras 2011). In mice, treatment with ALK1-Fc 
did not result in decreased tumour size, but seemed to 
remodel tumour vasculature, with increased perfusion 
and reduced hypoxia. A temporary improvement of 
tumour perfusion could result in a better delivery and 
eficacy of chemotherapy, and indeed, pretreatment 
with ALK1-Fc made tumours more sensitive to cisplatin, 
repressing disease progression (Hawinkels et  al. 2016). 
BMPs (particularly 9 and 10) may thus have an important 
role in primary tumour and bone metastases vascular 
remodelling, and not only angiogenesis itself. Targeting 
ALK1 and its ligands are the focus of ongoing clinical 
trials for anti-angiogenic therapies in breast cancer and 
other solid tumours, the results of which are awaited with 
interest.
Conclusions
Considering the prospect of relapsed disease and 
treatment resistance in breast cancer patients, and the 
signiicant burden of skeletal metastases in particular, we 
currently have only palliative measures for skeletal related 
events, and no bone-speciic predictors, biomarkers or 
preventative therapies for bone metastases.
Aberrant expression of BMPs and BMP signalling 
has been implicated in breast cancer and disease-speciic 
bone metastasis. BMPs are, as the evidence suggests, part 
of a highly complex, contextual and contrary signalling 
pathway, where balance is key to effect. The more recent 
studies have demonstrated BMP signalling activity in 
both breast primary tumours and bone metastases, 
contributing to EMT, angiogenesis, invasion, stemness 
and quiescence, bone-related phenotypes, osteogenesis 
and osteolysis.
These indings collectively indicate a promising 
therapeutic value for BMPs and their antagonists in the 
management of bone metastases by inluencing the 
propensity to disseminate to and survive in the bone 
microenvironment. In altering the balance of bone 
turnover to reduce osteolysis and the morbidity associated 
with it, they may also be a useful adjunct to the RANKL 
inhibitors currently used to palliate osteolytic lesions. 
The current clinical trials targeting ALK-1 BMP receptors 
to inluence tumour angiogenesis and effectiveness of 
chemotherapies clearly show that the BMP pathway 
contains a wealth of potential.
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